eXoZymes (EXOZ) AI Stock Analysis

16 Followers

eXoZymes

(NASDAQ:EXOZ)

Select Model

Rating:41Neutral

Price Target:$4.50▲(2.27% Upside)

Action:reiterated

Date:10/16/26

The score is primarily held down by weak financial performance (no revenue, widening losses, and ongoing cash burn) and a strongly bearish technical setup with the stock trading well below key moving averages. Valuation signals provide little support due to negative earnings and no indicated dividend.

Positive Factors

Reduced debt and moderate leverageLower debt and moderate leverage provide some financial flexibility relative to the company’s ongoing losses. This reduces the immediate burden of debt service and leaves more capacity to direct available resources toward operations, development, or future financing needs.

Negative Factors

No revenue and expanding lossesThe absence of revenue means the business has not yet demonstrated commercial traction or a recurring operating engine. Expanding losses further indicate that current activity is consuming resources without offsetting sales, leaving profitability and self-sustaining growth dependent on future execution.

eXoZymes (EXOZ) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $38.15M
Dividend Yield: ―
Average Volume (3M): 8,604
Price to Earnings (P/E): -3.7
Beta (1Y): 1.28
Revenue Growth: ―
EPS Growth: -21.64%
Country: US
Employees: 32
Sector: General
Sector Strength: 55
Industry: Biotechnology

eXoZymes Business Overview & Revenue Model

Company Description

eXoZymes, Inc. operates as a development stage biotechnology company. It focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing. The company was formerly known as Invizyne Technologies, Inc...

How the Company Makes Money

null

eXoZymes Financial Statement Overview

Summary

Financials reflect an early-stage biotech profile: no revenue, widening net losses (about $10.2M TTM), and persistent cash burn (about -$7.1M TTM free cash flow). The balance sheet is a partial offset with reduced debt (~$0.74M TTM) and moderate leverage (debt-to-equity ~0.20), but equity volatility and deeply negative ROE keep overall financial strength weak.

Income Statement

12Very Negative

Balance Sheet

46Neutral

Cash Flow

18Very Negative

Financial statement breakdown
Breakdown	TTM	Mar 2026	Mar 2025	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0	0	0	0	0	0
Gross Profit	68.61K	0	-267.38K	0	-147.75K	-59.41K
EBITDA	-10.51M	-8.98M	-5.59M	-1.80M	-1.18M	-1.15M
Net Income	-10.19M	-9.16M	-5.86M	-2.04M	-1.40M	-1.21M
Balance Sheet
Total Assets	7.98M	5.97M	13.03M	3.56M	2.69M	2.35M
Cash, Cash Equivalents and Short-Term Investments	5.65M	3.04M	9.72M	66.53K	558.57K	547.81K
Total Debt	1.09M	1.24M	1.39M	1.61M	608.77K	720.63K
Total Liabilities	4.33M	2.57M	2.61M	3.94M	1.31M	1.15M
Stockholders Equity	3.65M	3.40M	10.42M	-384.32K	1.37M	1.20M
Cash Flow
Free Cash Flow	-7.14M	-6.67M	-8.90M	-1.47M	-1.44M	-2.01M
Operating Cash Flow	-7.00M	-6.50M	-8.51M	-1.18M	-1.26M	-1.59M
Investing Cash Flow	-145.90K	-150.22K	-359.22K	-311.17K	-87.21K	-312.25K
Financing Cash Flow	5.81M	-27.71K	18.52M	1.00M	1.36M	2.31M

eXoZymes Technical Analysis

Technical Analysis SentimentNeutral

Last Price4.40

Price Trends

50DMA5.39Negative

100DMA5.89Negative

200DMA7.60Negative

Market Momentum

MACD-0.29Negative

RSI45.98Neutral

STOCH63.40Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EXOZ, the sentiment is Neutral. The current price of 4.40 is above the 20-day moving average (MA) of 4.22, below the 50-day MA of 5.39, and below the 200-day MA of 7.60, indicating a neutral trend. The MACD of -0.29 indicates Negative momentum. The RSI at 45.98 is Neutral, neither overbought nor oversold. The STOCH value of 63.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for EXOZ.

eXoZymes Risk Analysis

eXoZymes disclosed 47 risk factors in its most recent earnings report. eXoZymes reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks

1.Management has concluded that there is substantial doubt about the Company's ability to continue as a going concern.Q2, 2026

2.Changes to United States tariff and import/export regulations may have an adverse effect on our business, financial condition and results of operations.Q2, 2026

3.Government Action on tariffs and research grants and other funding may impede our ability to conduct our research and to raise capital by and for our partner companies and other clients.Q2, 2026

eXoZymes Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

EXOZ against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
NCEL	48Neutral	$15.56M	8.26	21.75%	―	―	―
EXOZ	41Neutral	$38.15M	-3.67	-292.13%	―	―	-21.64%
BDRX	38Underperform	$1.26M	-46.41	-42.42%	―	―	97.97%

* General Sector Average

Performance Comparison

EXOZ and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
EXOZ	Exozymes Inc.	4.40	-11.60	-72.50%
BDRX	Biodexa Pharmaceuticals Plc	2.48	-211.12	-98.84%
ADTX	Aditxt, Inc.	0.04	-1233.32	-100.00%
NCEL	Newcelx Ltd.	2.72	-1.17	-29.97%
VRAX	Virax Biolabs Group Ltd. Class A	0.79	-10.78	-93.17%

eXoZymes Corporate Events

Business Operations and StrategyRegulatory Filings and Compliance

eXoZymes Highlights Investor Presentation for Capital Markets Outreach

Positive

Oct 9, 2026

On October 6, 2026, eXoZymes Inc. prepared an investor presentation intended for distribution to investment bankers, offering participants, and existing and prospective investors. The document, filed as an exhibit, is designed to support the company&...

Shareholder Meetings

eXoZymes Sets Date for 2026 Shareholders Meeting

Neutral

Sep 18, 2026

eXoZymes announced that it scheduled its 2026 annual meeting of shareholders for November 13, 2026, setting a formal timeline for its upcoming governance and voting activities. The company established September 15, 2026 as the record date to determin...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 16, 2026

eXoZymes AI Stock Analysis